Digital health’s dilemma: There ain’t gonna be any middle (sized hospitals) any more

Between ViVE and HIMSS, much of healthcare IT has spent the waning days of winter perusing rows of vendors in expo halls. As the digital health market has matured over the last few years, the shiny objects on display seem to be fewer and farther between. Companies that were selling overvalued vaporware are increasingly disappearing, either going out of business or (much like my old, beloved Honda Fit) getting acquired for the technological equivalent of spare parts.

At the same time, and not necessarily coincidentally, investors and health systems alike have become savvier buyers. They have a far better understanding of what digital health products they actually need, as opposed to the products that look good in a pitch deck but will only add clinical, operational, or technical complexity. The side eye the industry is giving generative AI is a good example of this: Executives are happy to automate payment processing or clinical documentation, but they maintain healthy skepticism about most other use cases.

This maturation of the market is a good thing. Health system buyers are a lot less likely to get fooled, and they’re a lot more likely to get something that complements – if not directly integrates with – the clinical systems and workflows they already have in place. Meanwhile, the products that pass the test continue to get noticed. Instead of playing 4D chess to convince the market they’re The Next Big Thing, they can just explain what they do and why customers choose them. In other words, they can let the results speak for themselves.

That said, I worry the market for digital health vendors to sell to is shrinking. One reason is increased competition. As market-leading products gets better, those around them strive to improve as well. (I wish the 2024 Boston Red Sox were taking this lesson to heart, but that’s another topic for another day.) As the also-rans burn out or fade away, the bar gets higher for everyone else.

Smart vendors will be able to respond to competitive threats. They always have. I’m not sure they can respond as well to the other challenge that’s looming: A shrinking customer base.

Everything’s bigger in enterprise IT

There are oodles (official, technical term) of categories of digital health vendors who find themselves essentially competing with technology giants. Epic is beefing up analytics. Microsoft is pumping resources into ambient clinical voice. Google is striving to be a longitudinal patient record, among other things. Oracle is trying to bridge gaps between EHR and non-clinical systems like ERP. Everyone’s focusing on process automation.

Large hospital systems have longstanding relationships with these big vendors. They can support the scale of their implementations, not to mention the computing needs of their research efforts. It’s a lot easier for them to add a few line items to an existing contract for a new product (even if it costs more) than it is to ramp up a pilot with an unproven (to them) product.

In fact, a recent report from KLAS and UPMC found 70% of health systems are planning to adopt AI tools from their incumbent EHR vendors. That’s bad news for anyone pitching a standalone AI solution, no matter how firmly founders believe they are uniquely positioned to solve a problem . Plus, as an experienced developer put it on Twitter, incumbent vendors know their customers’ needs a lot better than a startup that can only speculate from afar.

On the other hand, small hospital systems (especially in rural areas) are literally trying to keep the lights on. They’d be interested in automating RCM if they had an actual IT department instead of two Help Desk employees trading morning and evening shifts. They’d be interested in SDoH data ingestion if there was a qualified data scientist living within 100 miles willing to accept a nonprofit’s salary. They’d be interested in a digital front door that increases acquisition and retention rates if they weren’t losing money on every new patient they got.

A shrinking customer base

That leaves digital health vendors to compete for the middle: The hospitals that aren’t too small to fear going out of business in a few months and aren’t too big to already have massive contracts with Big Tech in hand. These are great organizations to pitch. By and large, they know they have work to do, they’re committed to changing for the better, and they’re willing to take a chance on scrappy startups that remind them a lot of themselves.

The problem, to borrow from Pearl Jam’s “Porch,” is that market trends suggest there ain’t gonna be any middle any more. The uncertain future of the small, independent hospital has left many leaders to consider acquisition as the only option for staying open.

That will leave digital health vendors in a bind. Small hospital systems may fall in love with scrappy startups and their solution for any number of operational efficiencies, but their new corporate overlords are going to want everyone on the same enterprise-ready system. After all, it’s easier to manage one vendor and optimize one system than it it to juggle a dozen, especially if the software is merely adjacent to something as integral to operations as EHR, imaging, or RCM.

Ultimately, and unfortunately, it’s not going to matter how good the digital health solution may be. Unless the company is doing something truly transformational, it’s likely to lose out to the incumbent that has already shown executives it can deliver what it promised – or has enough leverage to walk away altogether if a customer is contemplating a standalone solution instead of turning on the incumbent vendor’s module that, philosophically if not technically, does the same thing.

Possible paths forward

I feel like this scenario leaves digital health companies with four paths forward.

Get in an enterprise app store and pray. This seems like a common strategy. On the face of it, it makes sense. Once potential customers see that you integrate with what they already have, your value proposition is a lot easier to prove. The challenge is making sure the new App Store Certified badges on your website don’t lead to complacency. Even if you’re the first vendor in your given market category (more on that later), others are sure to follow. The bigger danger with complacency, though, is that there’s no guarantee your gracious app store host isn’t thinking about how it can develop the same technology right into its application and, in a release cycle or two, quietly no longer have a need for you. (After all, as noted, most IT teams would rather manage another module for an existing application than a brand-new one, even if the new one is better, faster, stronger, etc.)

Get acquired by Big Tech. Hey, if you can’t beat ’em, join ’em. This route seems to make the most sense for companies that have done about as much as they can with the product they have without turning into a consulting firm. Offering services is a lot different than offering products. Even mature, grounded startups will struggle to compete – not just against standalone consultancies but also the armies of implementation specialists that Big Tech employs. Of course, it may be difficult for a company to admit it doesn’t have much left in the tank and is ready to be sold, especially if its founder is still heavily involved in day-to-day operations. (Then again, issuing minor improvements in multiple product releases in a row isn’t going to wow many customers, especially if they start to see Big Tech catching up to you.)

Stand your ground in a niche. Those vendor lists routinely published by CB Insights, KLAS Research, and the like are chock full of healthcare technology sub-markets. Sure, anyone with enough marketing money can create their own category. However, the bigger picture is a point that people smarter than me have made several times: Healthcare is in fact hundreds of billion-dollar markets, in large part because there are hundreds of processes that need to be optimized and modernized. Becoming a leader in a single niche – instead of, say, reinventing medical records or claims processing – may be a better recipe for success. (The challenge is if the niche turns out to be too small, as we’re seeing with a lot of condition-specific care management products. Even if they’re end-to-end, and even if they demonstrate fantastic outcomes, their value is sadly quite limited to a single condition.)

See what you can offer to other markets. This is admittedly contrary to my previous point, but there are certain healthcare problems – stuff like data aggregation, enrollment, engagement, and billing – that transcend the industry’s various vertical markets. (Here, I’m thinking provider, payer, integrated provider-payer, pharmacy, pharmaceutical, retail health, urgent care, and telehealth.) This is tricky: The value proposition for each healthcare vertical is different, as is the overall readiness and willingness to address the given problem. At the same time, if a digital health company can convince multiple stakeholders already working together that it has the chops to solve a shared problem, then it has a pretty compelling case to make for the larger market. (The key is already working together: Get the larger stakeholders to advocate for you on your behalf. That way, you already have a foot in the door and a cup of coffee waiting for you.)

It’s all about priorities

There’s no right answer for what those oodles of digital health vendors ought to do. Nor do the options outlined above guarantee success. Aiming to be acquired may look good on paper, but at a time when companies seem willing to lay off like 10% of workers before they can finish breakfast, eliminating the proverbial redundancies following a merger will be horrible for current morale and future recruiting.

Or, take pivoting into another market. Life science seems like a safe bet, as most firms are flush with cash and are crying out for more insight into patient needs and wants throughout the drug development life cycle. But can you support workflows that are likely unfamiliar to you – and can you add value above and beyond what the dozens of data aggregators targeting this market are already doing? Retail health and brick-and-mortar urgent care seemed like a safe bet, too, but then everyone realized it was not, in fact, magically profitable to create a brand-new entry point into the care delivery system two aisles over from the celebrity gossip magazines. (Everyone, that is, except the skeptics shouting that from the very beginning. Admittedly, I wasn’t one of them.)

As this is a free blog, I’m not a paid consultant, and my master’s degree is in history and not business administration, I can conclude with wishy-washy statements. If you’re a digital health vendor staring down your future, here’s my advice to you: Try to figure out what’s right for your company, your customers, your technology, and your people – and also figure out in what order you prioritize those four things. I doubt this will be easy, but I think it will help companies make an exit on their own terms.

Hopefully, Panda Health’s Predicted Digital Health “Shakeup” Won’t Be Too Hasty

Earlier this summer, application marketplace Panda Health released a reported called The Great Shakeup suggesting that upheaval is coming to the digital health landscape.

The rationale is sound. At the beginning of the pandemic, hospitals and health systems implemented just about any technology application that would enable them to maintain care continuity, if not keep them in business. Given the severity of the need, the typical buying cycle of 12-18 months was truncated significantly – in some cases, to 12-18 hours. Considerations like system integration, workflow compatibility, and change management were an afterthought at best.

This was understandable given the circumstances. But three years have passed. That’s an important milestone if for no other reason than, as Panda Health points out. the typical contract with a digital health vendor is three to five years.

In other words, it’s renewal time. Given that health system leaders have had a lot of time to reflect on their decisions, things might get ugly.

Lots of churn in telehealth, as one might expect

In an interview with Healthcare IT Today (a client of mine), Panda Health President and COO Ryan Bengtson said the highest level of vendor churn is expected to be in the technology categories of telemedicine and remote patient monitoring.

As the saying goes, this is shocking but not surprising. As I wrote back in April, telehealth has evolved from a necessity to a luxury. Absent a transition to full-scale value-based care, telehealth only really makes sense in behavioral health and for Medicare beneficiaries being seen under an accountable care organization (ACO) model. It also just so happens that the market is ripe with point solutions representing seemingly every medical specialty or point of care within the patient journey.

Take these two points together and it’s clear that smart health systems will be taking a long, hard look at their telehealth portfolio. Bengtson said any point solution that doesn’t integrate with a health system’s larger clinical technology stack may be in trouble. Add to that the omnipresent desire to reduce the complexity and cost of managing multiple products that do the same thing and it’s clear that vendor consolidation is coming. (There’s probably a Game of Thrones reference to be made here, but I never watched it.)

An unclear path forward

The next couple years are going to be very interesting, in part because some of the most obvious solutions, like objects in the rearview mirror, are less appealing than they seem.

Platforms could solve the technology side of the point solution problem. It makes sense to host all the telehealth stuff in one place, right? But unless there’s some way to curate disparate telehealth offerings, surface recommendations to patients in the interface they’re familiar with (a portal, probably, sigh), and ensure that clinicians can connect to them as well, the care experience isn’t going to be much better.

Plus, doing the platform thing right really requires an all-or-nothing approach. It’s not just telehealth; it’s medication adherence, chronic care management, remote monitoring, and basically anything else that involves provisioning care in between appointments. After all, if some solutions are on a platform but others are floating harmlessly somewhere on the Internet, then there’s not really much incentive to go to the platform. Frustrated patients will abandon the telehealth experience in favor of the sometimes inconvenient but always familiar in-person appointment. As usage rates plummet, even the biggest technophile decision-makers will have a hard time justifying a renewal – and point solutions will suffer.

What about going all-in with a big vendor? They’ve been acquiring companies or otherwise expanding into specialties left and right, haven’t they? Well, yes – and Wall Street seems far from impressed with this approach. Teladoc Health is trading at 8% of its winter 2021 peak. Amwell is trading at just over 6% of its peak, also from winter 2021. (Both are as of July 20.) To roughly paraphrase Hello Health and Sherpaa co-founder Dr. Jay Parkinson, there are only so many cases of ink eye you can treat virtually.

The problem – as I also pointed out in my recent treatise and as others have said many, many times as well – is that patients are going to seek telehealth no matter where it comes from. They don’t care if it’s from their hospital, from retail health, from their insurer, from a concierge service, or from an app that advertises a coupon code on Facebook. Health systems that ignore this risk losing a lot of patients at the top of the funnel, only to see them in the ED years from now and not know a damn thing about their recent medical history.

All of this is to say that a cautious approach to digital health vendor churn may be warranted. Just because the revenue or year-over-year usage data is in the red doesn’t automatically mean a solution should get the axe. Health systems need to look a little deeper and consider who’s using a telehealth product and what they’ll do if it goes away.

If there’s a suitable alternative, or if they’ll maintain strong enough ties to stick around, then the health system may be able to get along without it. But if patients may walk out the (digital) (front) door and may not come back, then the telehealth tool may be worth keeping. Rewriting a vendor contract is harder, but engaging with patients who have come and gone is even harder.

Telehealth’s Day of Reckoning

In the board game Life, there’s a space near the end marked Day of Reckoning. At this point, players have to decide if they think they have enough money to win. If they think they do, they can keep playing. If they don’t, they place everything they have on one number (out of 10), spin the dial, and hope for the best while knowing there’s a 90% chance they’ll go bankrupt.

I’m beginning to think healthcare is facing a day of reckoning of sorts when it comes to telehealth. Three years after the pandemic, when sudden (and largely successful) adoption had us wondering what telehealth’s future looks like, utilization has plateaued. That has put organizations in the difficult position of trying to decide if they can move ahead with what they have – that is, if their existing telehealth offerings are enough to compete with All Those Disruptors Out There, not to mention the health systems down the street – or if they need to gamble on a strategy with a slight chance of succeeding.

It’s an unenviable position. Extenuating circumstances aren’t making the decision any easier for health system leaders who must tread carefully with telehealth investments but face external pressures to Do Something and avoid being disrupted by forces they can neither control nor predict. Vendors are equally challenged, as their accumulated expertise in the use case they have so carefully developed, tested, and rolled out smacks into the stark reality that point solutions (save for behavioral health) may not have a place in the long-term future of telehealth. Fortunately, knowing that utilization has plateaued but that demand remains strong can give the industry some direction – not a lot, admittedly, but some – for determining where to go next.

Providers are using telehealth – just not all that often

Recently, the Office of the National Coordinator for Health IT (ONC) released data that put a pretty positive light on telehealth. The agency’s report suggested that 85% of physicians used telehealth at least once in 2021, up significantly from 15% in 2018-2019. In addition, 62% of physicians were fully or somewhat satisfied with their use of telehealth. Tellingly, there was little urban-rural divide when it came to utilization – an important data point in light of concerns that rural areas are in danger of being left behind as telehealth takes off. (Slightly higher percentages of telephone and video conferencing for telehealth in rural areas, as opposed to dedicated telehealth platforms, helps to explain how physicians and patients may be closing the gap.)

Peeking behind the curtain, though, the data presents some concerns.

  • Utilization is highest among physicians in a value-based care model such as an accountable care organization (ACO) and affiliated with large health systems. It’s lowest among physicians in small practices. (We’ll dive into this later.)
  • The majority of physicians (53%) use telehealth for less than 25% of their total patient visits.
  • A telehealth platform integrated with an electronic health record (EHR) – the option that arguably provides the best continuity with in-person care – is the least commonly used form of telehealth across all types of physicians, payment models, and care sites.

In other words, utilization and access aren’t being distributed as as equitably as the industry would like. Provider interest is there, but it depends largely on how a provider is being paid and whether they have the resources to support the technology being used. Our long-held suspicions about who uses telehealth, it turns out, continued to hold true through the pandemic.

Aside from behavioral health, utilization seems limited

Additional data on telehealth utilization highlights other concerns about where utilization is headed. First, there’s the FAIR Health assessment of commercial health insurance claims. From January 2022 until December 2022, telehealth visits as a percentage of all claims remained largely steady at 5.5%. This is less than January 2021, when utilization hit 7.0%, but an increase from December 2021, when telehealth was less than 5% of all claims.

The more interesting data point to me is the dominance of behavioral health, which accounted for roughly 60% of all telehealth claims. That means the dozens of other medical specialties – including primary care – only accounted for 40% of telehealth claims. It roughly aligns with McKinsey’s take on telehealth, too, which shows that telehealth accounts for 54% of all behavioral health visits but 14% of medical specialty visits and just 5% of procedural specialty visits. (Again, it confirms long-held suspicions about who is and isn’t interested in telehealth.)

Next, there’s the Bipartisan Policy Center’s assessment of Medicare claims. This report pegged telehealth at roughly 6.8% of all claims for the first nine months of 2021, with behavioral health accounting for a little more than one-third of all telehealth visits. (Primary care accounted for nearly 27%, which is far more than in the under-65 population.) If Medicare claims followed the same trends as reflected in FAIR Health’s look at commercial claims, then the 2022 figures are probably a bit lower.

Looking at these data points, and then looking at them in the context of the ONC data, it’s hard not to nod in agreement with the early 2022 assessment of Trilliant Health, which came to the following sobering conclusions about telehealth’s broader impact on the economy:

  • Nearly 46% of patients had just one telehealth visit in all of 2021, and another 34% had fewer than five. That explains, per the ONC’s data, how so many physicians had used telehealth “at least once” and also only used telehealth for a small percentage of their encounters.
  • In only one specialty – behavioral health – is telehealth a “substitute good” for in-person care. In all other specialties, including primary care, when choice isn’t constrained, patients prefer in-person care. (That doesn’t account for a return to the requirement for in-person visits prior to remote prescriptions of controlled substances at the end of the public health emergency, which the American Telemedicine Association is not too happy about.)
  • Accounting for the wide disparities in reimbursement rates for virtual care episodes as compared to in-person care episodes, telehealth’s potential total share of the healthcare market is all of 1%.

Is telehealth a luxury now?

Clearly, healthcare faces a dilemma. The technology that quite literally saved the industry in the spring of 2020 is no longer a commodity. Two separate studies, one of the general patient population and another of patients in oncology, both found that preferences have shifted to in-person visits, even if in-person visits were to cost more out of pocket that virtual visits.

In fact, Trilliant Health likened telehealth’s total addressable market to that of a luxury good, given that the total number of patients using telehealth more than several times a year falls at less than 10 million. The comparison of a virtual healthcare visit to a BMW or a Peleton may have ruffled some feathers, but it’s not that far off base.

One of telehealth’s most persistent criticisms has been that it’s largely available only to healthcare organizations that can afford to support it at scale and patients that can afford the technology to access it regularly. Audio-only telehealth filled some access gaps in the early days of the pandemic, but it has always remained a fraction of the total number of virtual visits. Until that changes, patients without broadband, reliable cell signals, and unlimited data plans won’t bother with telehealth. The same goes for small office physicians who, as the public health emergency ends, can no longer use video conferencing software but don’t have the technology budget, expertise, or willpower to invest in dedicated telehealth technology.

The other main complaint is that, under current care delivery and payment models, telehealth only makes fiscal sense in two scenarios: When reimbursement for virtual care is at or close to parity for in-person care, and when enough patients are covered under a value-based contract such as a Medicare ACO. Linking these scenarios to the data presented earlier, the first example explains the popularity of telehealth for behavioral health, and the second example points to the higher adoption levels for primary care in Medicare. (If you think telehealth for low-acuity urgent care makes fiscal sense, well, I have some stock in publicly traded telehealth vendors to sell you. It’s pretty cheap.)

The idea of telehealth as a luxury good and not a commodity stings even harder when we recall McKinsey’s rosy projection from 2020 that telehealth would be a $250 billion industry. It doesn’t help that a share of 1% of the market also comes with the stigma of 1% – a figure that to many represents privilege, wealth, and ignorance of the true needs of everyone else.

The thing is, the 1% figure is probably pretty realistic. After all, the types of medical visits associated with telehealth (behavioral health, primary care, remote monitoring, follow-up, etc.) reimburse at a lower rate than in-person visits. This is obvious for things like inpatient procedures, sure, but it’s also true for specialty consults, imaging scans, and a host of other in-person encounters that require the use of expensive equipment or a discussion among multiple providers. It shouldn’t be surprising that telehealth’s total market share is significantly less than its total share of visits.

Plus, if you’re going to be 1% of a market, it might as well be healthcare, which as of 2021 is a $4.3 trillion industry in the United States. One percent of that is still $43 billion. Heck, the far more impressive-sounding $250 billion is still only 5.8% of that figure – which isn’t too far off from telehealth’s utilization as a percentage of all visits.

Of course, there’s more to the story

It would be fine if the story ended here. Not great, not terrible, but fine. Telehealth would be a niche market, albeit a $43 billion niche market, focused largely on behavioral health and occasionally on primacy care, with additional use cases available thanks to a tech-savvy physician group here, a willing payer there, an innovative vendor over here, and a large employer over there. It might integrate with the EHR, or it might not – but since it’s not really being used for high-acuity care or specialty care all that much, there really isn’t all that much missing from the patient record at the end of the day. It would probably continue to drive inequity in care, at least initially, though continued investment in technology infrastructure could combat that to a certain degree.

It would be a fine ending because, for once, we’d actually know where telehealth stood. Before the pandemic, writers like me put out stories every year with the theme “This is finally the year for telehealth to take off!” Analysts and consultants would crunch numbers and grossly exaggerate telehealth’s projected total impact on the industry. (If you’d have projected a market cap of $12 jillion for telehealth as it surpassed eleventeen percent of all visits, you honestly wouldn’t have been that far off.) Vendors would claim their total addressable market was every American with a smartphone with no regard for the need to narrow the digital divide before things like continuous remote monitoring or synchronous visits would be possible.

Now that healthcare first had no choice but to embrace telehealth to survive and then returned to in-person visits in all cases but behavioral health, we know what telehealth represents. We know the limits it faces broadly in fee-for-service medicine and specifically in so many types of specialty care. We know that Wall Street is a lot less bullish on telehealth than it once was. It’s like when your favorite baseball team begins the season with promise but wakes up on May 1 in last place with a 6-20 record. We know exactly where we stand, whether we like it or not.

The story doesn’t end here, though. There are a few important reasons why.

One is the demonstrated impact on clinical and financial outcomes. An Epic Research evaluation of nearly 19 million telehealth visits to primary care found that 61% of visits didn’t require an in-person follow-up within the next 90 days. A second paper, which got a lot of press when it was released last year, found that telehealth is as good or better than in-person care on 13 of 16 HEDIS measures (Health Care Effectiveness Data and Information Set). One paper even showed that remote monitoring improved blood pressure monitoring “despite a nationally observed disruption of traditional hypertension care” during the pandemic. In other words, telehealth is quite effective when it’s done right.

The second reason is that telehealth in behavioral health has shown the industry what can be possible. There are startup CEOs, healthcare executives, and even physician champions looking at behavioral health, with 54% of all visits being done virtually and a 60% share of all telehealth claims, and wondering why their specialty of choice can’t do better than a handful of visits here and there. Arguably, no one else will achieve such lofty numbers, to be sure, but even doubling the number of virtual visits in any given specialty will represent significant progress – and begin to provide evidence to contrarians simply convinced that virtual care cannot work in their specialty. At some point, the other shoe will drop.

Plus, at the risk of sounding cliché, patients will start to come to expect it. Anyone who frequently sees a behavioral health professional virtually will start to wonder why every other specialist demands an in-person visit. Anyone who has had fairly seamless virtual visit experiences – whether for check-ins during the pandemic or for behavioral health appointments using purpose-built telehealth products – will ask why the experience is so much more clunky everywhere else in the hospital. Even those who understand the complexities of managing their chronic condition will question why they must go to the office to review numbers that both they patient and their provider can see in the same database when they can talk to a behavioral health provider from their couch.

Finally, the concept of the “digital front door” doesn’t seem to want to go away. Vendors continue to push it, and health systems continue to invest in it. Even with telehealth utilization at less than 6% and market share at 1%, they’re scared of losing patients to entities that do telehealth better – whether it’s the standalone app advertising discount visits on the subway, the service available through the region’s largest employer at no cost to employees, or the payer that knows that getting more members to use telehealth gives it leverage come contract negotiation time. Even with executives touting the value of personal relationships with physicians and the wonderful amenities in their new brick-and-mortar facilities, they’re scared that a digital front door that only opens partway will be the end of their business, especially if patients say there’s no discernable difference to the patient experience when they use virtual care.

Now what? It pays to choose widely

So what, pray tell, can the industry do as it faces its day of reckoning with telehealth? How should the industry move forward knowing that utilization is basically flat but demand exists in pockets here and there – that opportunities for expansion are paradoxically both constrained and yet available under the right circumstances? Well, it’s complicated.

Under current reimbursement and care delivery models, point solutions will have a rough go unless they serve 1) behavioral health or 2) a specialty that has seen demonstrated improvement to clinical and financial outcomes in value-based care models. In the second case, vendors may need to set their sights on specialty physician groups, as the business case will be easier to make for these stakeholders than for large health systems hosting dozens of specialties. The one exception here may be post-natal / early childhood care; since many state Medicaid programs are extending coverage for the first 12 months or more of a child’s life, we can expect a corresponding push for broader care coordination and a small but significant role for telehealth under such a new care model.

Along the same lines, any new value-based care model – whether designed by Medicare, Medicaid, or commercial insurers – should consider telehealth from the perspective of the utilization threshold that can be reasonably expected for a given specialty. Obviously, some specialties are literally more hands-on than others; care pathways, treatment plans, and patient engagement approaches also differ tremendously. Figuring out where and when encounters can be handled virtually will require significant work, but I think it’s imperative to get that right before any sort of value-based specialty care model is put in place. Otherwise, the Powers That Be could easily be seen as imposing their will on providers who either feel they’re being asked to use telehealth when it doesn’t make sense or are given a bar that’s so low that they only need to see a handful of patients virtually a handful of times to hit the mark.

Meanwhile, health systems need to look long and hard at telehealth’s role in their near-term business strategy. I know that’s not exactly groundbreaking advice, but leadership needs to decide if they’re comfortable with sticking to telehealth for behavioral health (and possibly primary care or urgent care) for the time being, or if they feel the need to broaden their horizons in the face of unforeseen competition. If it’s the latter, where’s the greatest danger to their business, and does it make sense to invest time, resources, energy, and attention into rolling out technology that will apply to roughly 6% of visits and 1% of revenue?

It’s an unenviable Catch-22. Most health systems likely have to spend money to make money on telehealth, and they don’t have much to spend given the many financial pressures they face – but those retail, pharmacy, and digital health competitors do. These circumstances only put pressure on health systems to act quickly, which has never been their preferred approach to telehealth adoption, what with so many purpose-built applications serving one business unit within one building and never scaling much beyond that.

Those types of solutions proliferate because, up until March 2020, that was the best way for most vendors to get in the door: Present a compelling use case tied to a specific clinical outcome for a given population, get buy-in, and work alongside provider staff to get the ball rolling. It’s hard to blame vendors for taking that approach, especially when large platforms have struggled to integrate both technology and service offerings – and when, stop me if I sound like a broken record, it’s worked so well in behavioral health.

At the same time, the integrated platform appears to be the more pragmatic path forward. It gives patients a more unified experience (especially if they must navigate multiple specialties), it lets health systems deploy to new specialties without custom development, and (implemented properly) it gives point solutions something to plug into so they aren’t lost in the shuffle (and a partner that can help them scale – or that can acquire them, if that’s the end goal).

I wish there was an answer to the “Now what?” question beyond “Think before you leap.” (I know if I were paying a consultant, and they came up with that after months of work, I’d be none too pleased…) At the same time, every healthcare stakeholder is looking at telehealth for different reasons both now and in the future, so I don’t think a specific piece of advice is going to apply.

However, I do think that looking at the evidence presented here of where and how telehealth utilization has stuck, and coupling that with business priorities, will help steer organizations toward a better decision. It won’t result in enterprise-wide deployment or a sudden digital transformation, but it also won’t leave leadership in a position where they feel they have no choice but to spin the wheel and hope for the best.

New Clips (Or, Why I’ve Been Too Busy to Write Blog Posts)

When I was laid off in early April, I had no idea how the subsequent weeks were going to play themselves out. My mind wavered between immediately finding work and spending months searching. Some days offered great promise; others yielded nothing.

It turns out – very fortunately – that things have ended up being much closer to the former than the latter. (This explains why I haven’t been writing as much on this blog as I would have expected several weeks ago.)

First, I was lucky to get some freelance assignments from former clients.

Then, I received some assignments from old healthcare IT contacts I’d never written for but frequently talked to (sometimes on Twitter and sometimes in real life). A lot of this work has been marketing and research content that’s still in production, but I do have one link to share.

Finally, I took on a short-term contract position with the consulting firm Healthcare IT Leaders. The role primarily involves working with consultants on their content, to help them demonstrate expertise and ultimately land another consulting role, but I have had a chance to do a bit of writing for myself.

All in all, I have had a lot going on. Frankly, under normal circumstances it would likely be a bit too much.

My rationale for staying busy right now is twofold. One, it’s helping to set me up for when my contract role is over and I will need more assignments. Two, being productive when there’s not much else to do keeps me focused and, in a way, grounded.

That said, if you find yourself where I did several weeks ago – with no full-time role and a need for paid writing assignments – please feel free to get in touch. A big part of how I was able to get assignments, and land firmly on my feet after getting laid off, was through personal referrals. I’d be happy to pay it forward if I can.

What’s in Store for Telehealth?

One of the more pleasant surprises in the health care industry’s response to the COVID-19 crisis — if there are such things as pleasant surprises — has been the near-universal embrace of telehealth services by all stakeholders. Insurers have waived copays for many types of virtual visits. Providers have dramatically expanded virtual care options. State governments have lifted restrictions on who can practice as well as how much they can bill for. Vendors have vastly expanded services to meet demand. Vendors, providers, and insurers have all rolled out logic-based symptom-checker apps.

For a market segment that has all too often been defined by starts and starts, recent weeks have offered validation of telehealth’s value proposition. Telehealth has helped to keep low-acuity patients away from brick-and-mortar health care facilities, thereby reserving bed spaces for patients with COVID-19 (and others with high-risk conditions). Within the hospital, telehealth has also allowed health care professionals to reduce their physical touchpoints with patients with COVID-19, thereby reducing their own risk of contacting the virus.

If telehealth can prove its worth in a crisis, it stands to reason, then why not once the crisis subsides? As I heard from one executive in a conversation related to my last role, his health systems’s 5-year trajectory for encouraging digital health engagement was truncated to 3 weeks because of COVID-19 — and, he added, “the pendulum will not swing back.”

Many have expressed optimism that these circumstances will, once and for all, encourage the industry to adopt telehealth as a viable alternative to in-person care (in the right scenarios) and to dismantle the various technology, reimbursement, and regulatory barriers that have hindered adoption (and, some would further argue, have defied common sense). The so-called “digital front door to care,” it seems, is now open for business.

This may be the case, and I am optimistic that telehealth can address some of health care’s challenges. Few would disagree that the industry desperately needs more options for readily accessible low-acuity care that diverts patients from the ER. Urgent care is one option, sure, but if patients can receive care without leaving home or the office at all, then their lives (and their care journey) face even less disruption. What’s not to like?

However, health care’s recent history of rapid technology adoption suggests that immediately embracing telehealth could end up doing more harm than good. Meaningful use was unnecessarily painful for many health systems, as they simply layered electronic health records on top of analog workflows for gathering information and delivering care. More than a decade later, health systems are still struggling to optimize workflows, and most would admit that they feel like they’re stuck with EHR software that hasn’t done what they hoped it would do.

Telehealth presents the same danger. Yes, telehealth adoption in response to COVID-19 has been organic, whereas EHR adoption was mandated — but the same impact of rapidly scaling telehealth is nonetheless possible. If health systems simply bolt virtual visits onto existing clinical workflows that emphasize in-person care delivery, diagnosis, and treatment, the end result won’t be pretty. It doesn’t take much imagination to see a patient dialing into a virtual visit, only to be told that the best option for care is to come to the office. That’s costly, inconvenient, inefficient, and frustrating for the patient and the health system.

On top of the concern that telehealth could be meaningful use all over again, I see two additional and related challenges.

  1. Many hospitals and health systems, hit hard by the financial double whammy of costly COVID-19 treatments and cancelled high-revenue elective procedures, will be a fraction of what they once were, if they remain open at all. Getting people in the door will be mission-critical for survival. Offering virtual visits at a fraction of the (reimbursable) cost, especially if it requires additional investment in technology infrastructure, will not be — even though it presents the opportunity for downstream patient retention for future services.
  2. Patients have a lot of options for telehealth. There are “traditional” health care providers but also health plans, employers, retail clinics, direct-to-consumer apps, third-party conveners, and various combinations thereof. If any of those offerings are better, stronger, or faster than what a health system can do, then that system is going to lose its low-acuity patients. If that happens, then the post-COVID hospital could then look a lot like the mid-COVID hospital. It will be filled solely with very sick patients and very overburdened staff, it will further exacerbate the gap between those who are ill and those who are well, and it will leave hospitals with far fewer opportunities to attract new patients and capture downstream revenue.

Telehealth in the United States clearly has momentum right now. It’s bringing value to patients, providers, and payers in ways that had been imagined but not realized until the COVID-19 crisis hit. But building on that momentum will require very careful thought. History tells us that implementing technology for the sake of implementing technology does not serve health care well. The industry would be wise to remember this lesson.